MitoQ before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether taking the supplement MitoQ before standard surgery can help treat triple-negative breast cancer. You would take MitoQ for a short time between diagnosis and surgery to see if it slows tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with triple-negative breast cancer that is confirmed by a biopsy.
- Your cancer has not been treated yet with any systemic therapy (like chemotherapy or targeted drugs).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You are willing to use effective birth control if you could become pregnant.
- You have a tumor sample (in a block or at least 20 unstained slides) that can be tested in the lab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.